Full history for every metric is available with a Kvantra account
HTG Molecular Diagnostics, Inc. (HTGM)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 15 | 22 | 19 | 9 | 9 | 6 | 6 |
| Operating profit | $m | -21 | -20 | |||||
| Net profit | $m | -19 | -16 | -19 | -21 | -17 | -22 | -20 |
| EPS reported | $ | -0.24 | -0.19 | |||||
| Operating cashflow per share | $ | -0.21 | -0.21 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.21 | -0.21 | |||||
| Free cash flow | $m | -18 | -17 | |||||
| Net debt | $m | -7 | -3 | |||||
| Book value equity | $m | 5 | - | |||||
| Book value per share | $ | 0.06 | - | |||||
| Number of shares | m | 88.93 | 221.41 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 65.81 | 7.92 | |||||
| P/S LTM | x | 55.74 | 0.17 | |||||
| P/FCF LTM | x | -19.25 | -0.06 | |||||
| EV/EBITDA LTM | x | -17.25 | 0.13 | |||||
| EV/Sales LTM | x | 54.58 | -0.39 | |||||
| Earnings Yield LTM | % | -6.09% | -50.59% | |||||
| FCF Yield | % | -5.19% | -1585.6% | |||||
| Quality | ||||||||
| ROE | % | -400.51% | -273.49% | |||||
| ROIC | % | -151.00% | -151.00% | |||||
| Operating margin | % | -327.19% | -327.19% | |||||
| Gross margin | % | 28.18% | 28.18% | |||||
| FCF/Sales | % | -289.51% | -289.51% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -28.52% | -28.21% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.81 | -4.23 | |||||
| Net Debt/EBITDA | x | 0.37 | 0.37 | |||||
| EBIT/Net interest | x | -24.31 | -24.31 | |||||
| Net debt/market cap | % | -2.08% | -328.14% | |||||
| Net debt/Equity | x | -1.37 | - | |||||
| Gross debt/equity | x | 0.90 | - | |||||
Company overview
Based in Tucson, Arizona, HTG Molecular Diagnostics, Inc. is a life sciences company dedicated to advancing precision medicine. They provide a comprehensive suite of products, including specialized instruments, assay kit consumables, and software solutions, all designed to automate sample processing and accurately profile various molecular targets. Their extensive portfolio features numerous molecular profiling panels, such as the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay (available in both EU and non-EU versions), HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq ALKPlus assay EU, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG immune response panel, and HTG mouse mRNA tumor response panel. The company directly distributes its instruments and consumables across the United States and Europe, while utilizing distributors for other international markets and specific European regions. Their diverse clientele includes biopharmaceutical companies, academic research centers, and molecular testing laboratories. Additionally, HTG Molecular Diagnostics, Inc. maintains a governing agreement with QIAGEN Manchester Limited. The company was founded in 1997 as HTG, Inc., and officially changed its name to HTG Molecular Diagnostics, Inc. in March 2011.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
HTG Molecular Diagnostics, Inc. (HTGM)
Based in Tucson, Arizona, HTG Molecular Diagnostics, Inc. is a life sciences company dedicated to advancing precision medicine. They provide a comprehensive suite of products, including specialized instruments, assay kit consumables, and software solutions, all designed to automate sample processing and accurately profile various molecular targets. Their extensive portfolio features numerous molecular profiling panels, such as the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay (available in both EU and non-EU versions), HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq ALKPlus assay EU, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG immune response panel, and HTG mouse mRNA tumor response panel. The company directly distributes its instruments and consumables across the United States and Europe, while utilizing distributors for other international markets and specific European regions. Their diverse clientele includes biopharmaceutical companies, academic research centers, and molecular testing laboratories. Additionally, HTG Molecular Diagnostics, Inc. maintains a governing agreement with QIAGEN Manchester Limited. The company was founded in 1997 as HTG, Inc., and officially changed its name to HTG Molecular Diagnostics, Inc. in March 2011.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free